Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

14/433 Publications

Methodology Clear all
  1. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025

    FibroTest-T2D Metabolic

  2. Toward non-invasive assessment strategies in autoimmune hepatitis.

    Jerez Diaz D et al. · World J Hepatol · 2025

    ActiTest FibroTest AIH

  3. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023

    FibroTest Metabolic

  4. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  5. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023

    FibroTest Metabolic

  6. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

    Rinella ME et al. · J Hepatol · 2022

    FibroTest Metabolic

  7. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022

    FibroTest COVID

  8. Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study.

    Majumdar A et al. · Hepatology · 2020

    FibroTest

  9. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018

    ActiTest FibroTest NashTest NashTest-2 +3

  10. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016

    FibroTest HBV HCV

  11. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012

    Metabolic

  12. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.

    Poynard T et al. · J Viral Hepat · 2008

    FibroTest HCV

  13. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication

    Poynard T et al. · Clin Chem · 2007

    FibroTest HCV

  14. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007

    FibroTest HCV

Showing the full result list. The page is server-rendered and not paginated.